The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling
Authors:
- Desiree H. FloydDFDesiree H. Floyd
- Alun HughesAHAlun Hughes
- Jingyu XiangJXJingyu Xiang
- Jochen G. SchneiderJSJochen G. Schneider
- Ozge UluckanOUOzge Uluckan
- Emanuela HellerEHEmanuela Heller
- Hongju DengHDHongju Deng
- Wei ZouWZWei Zou
- Clarissa S. CraftCCClarissa S. Craft
- Kaiming WuKWKaiming Wu
- Angela C. HirbeAHAngela C. Hirbe
Open Access
- 1 October 2012
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 122 (10) , 3579-3592
Abstract
The adenosine diphosphate (ADP) receptor P2RY12 (purinergic receptor P2Y, G protein coupled, 12) plays a critical role in platelet aggregation, and P2RY12 inhibitors are used clinically to prevent cardiac and cerebral thrombotic events. Extracellular ADP has also been shown to increase osteoclast (OC) activity, but the role of P2RY12 in OC biology is unknown. Here, we examined the role of mouse P2RY12 in OC function. Mice lacking P2ry12 had decreased OC activity and were partially protected from age-associated bone loss. P2ry12–/– OCs exhibited intact differentiation markers, but diminished resorptive function. Extracellular ADP enhanced OC adhesion and resorptive activity of WT, but not P2ry12–/–, OCs. In platelets, ADP stimulation of P2RY12 resulted in GTPase Ras-related protein (RAP1) activation and subsequent αIIbβ3 integrin activation. Likewise, we found that ADP stimulation induced RAP1 activation in WT and integrin β3 gene knockout (Itgb3–/–) OCs, but its effects were substantially blunted in P2ry12–/– OCs. In vivo, P2ry12–/– mice were partially protected from pathologic bone loss associated with serum transfer arthritis, tumor growth in bone, and ovariectomy-induced osteoporosis: all conditions associated with increased extracellular ADP. Finally, mice treated with the clinical inhibitor of P2RY12, clopidogrel, were protected from pathologic osteolysis. These results demonstrate that P2RY12 is the primary ADP receptor in OCs and suggest that P2RY12 inhibition is a potential therapeutic target for pathologic bone loss.Keywords
This publication has 83 references indexed in Scilit:
- Cancer to bone: a fatal attractionNature Reviews Cancer, 2011
- Find-me and eat-me signals in apoptotic cell clearance: progress and conundrumsJournal of Experimental Medicine, 2010
- Cdc42 regulates bone modeling and remodeling in mice by modulating RANKL/M-CSF signaling and osteoclast polarizationJournal of Clinical Investigation, 2010
- The InflammasomesCell, 2010
- Dissection of platelet and myeloid cell defects by conditional targeting of the β3‐integrin subunitThe FASEB Journal, 2009
- Pathway crosstalk between Ras/Raf and PI3K in promotion of M‐CSF‐induced MEK/ERK‐mediated osteoclast survivalJournal of Cellular Biochemistry, 2008
- APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in miceJournal of Cellular Biochemistry, 2008
- Regulation of death and survival in astrocytes by ADP activating P2Y1 and P2Y12 receptorsBiochemical Pharmacology, 2006
- The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid raftsProceedings of the National Academy of Sciences, 2006
- Enhanced pathological angiogenesis in mice lacking β3 integrin or β3 and β5 integrinsNature Medicine, 2002